Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial

<i>RASSF1</i> gene methylation predicts longer disease-free survival (DFS) and overall survival (OS) in patients with early-stage non-small-cell lung cancer treated using paclitaxel-based neo-adjuvant chemotherapy compared to patients receiving a gemcitabine-based regimen, according to t...

Full description

Bibliographic Details
Main Authors: Fatéméh Dubois, Maureen Keller, Julien Hoflack, Elodie Maille, Martine Antoine, Virginie Westeel, Emmanuel Bergot, Elisabeth Quoix, Armelle Lavolé, Laurence Bigay-Game, Jean-Louis Pujol, Alexandra Langlais, Franck Morin, Gérard Zalcman, Guénaëlle Levallet
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Cancers
Subjects:
non-small-cell lung cancer
rassf1a
dna methylation
paclitaxel
iap2
Online Access:https://www.mdpi.com/2072-6694/11/12/1835

Internet

https://www.mdpi.com/2072-6694/11/12/1835

Similar Items